Linked from

The 36 pages that link to Pharmacovigilance, each with the reason it gives.

• Adverse drug reactionNarrower topic: It gathers reports and evidence to identify risks that were missed before approval.

• ThalidomideNarrower topic: Thalidomide demonstrated why safety monitoring must continue after a drug reaches market.

• NephrotoxicityNarrower topic: Reports of kidney injury help identify medication risks after drugs reach wider use.

• Herb–drug interactionNarrower topic: Reports of suspected supplement interactions contribute to evidence about uncommon or poorly studied harms.

• Over-the-counter drugNarrower topic: Reports of harms from OTC use help regulators identify risks after products reach the market.

• AkathisiaNarrower topic: Better detection of medication-related akathisia depends on reporting and evaluating adverse drug reactions.

• European Medicines AgencyNarrower topic: The agency coordinates safety monitoring throughout a medicine's marketed life.

• Adverse eventNarrower topic: Adverse-event reports are a central source of safety information for this broader discipline.

• MetamizoleNarrower topic: Monitoring reports of blood disorders has influenced decisions about metamizole’s safety.

• MontelukastNarrower topic: Postmarketing safety reports helped identify concerns not fully captured before approval.

• ThiomersalNarrower topic: Monitoring systems evaluate suspected harms associated with vaccines and their ingredients.

• SalmeterolNarrower topic: Post-marketing safety monitoring helped identify risks associated with LABA treatment.